Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.

@article{Seltzer2004EfficacyOD,
  title={Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.},
  author={Ben Seltzer and Parvaneh Zolnouni and Margarita Nunez and Robert Goldman and Dinesh Kumar and John R Ieni and Sharon Richardson},
  journal={Archives of neurology},
  year={2004},
  volume={61 12},
  pages={1852-6}
}
OBJECTIVE To evaluate the efficacy of donepezil in patients with early-stage Alzheimer disease. DESIGN Multicenter, randomized, double-blind, 24-week, placebo-controlled study that enrolled patients with early-stage Alzheimer disease. Patients were randomized in an approximately 2:1 ratio to donepezil, 5 mg/d, for the first 6 weeks, with a forced escalation to 10 mg/d thereafter (n = 96), or placebo (n = 57). The primary efficacy measure was the modified Alzheimer Disease Assessment Scale… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 78 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

An integrated approach to the management of Alzheimer’s disease: assessing cognition, function and behaviour [abstract

  • D. Galasko
  • Eur J Neurol
  • 1998
Highly Influential
8 Excerpts

; 57 : 1942 ]

  • OL Lopez, JT Becker, S Wisniewski, J Saxton, DI Kaufer, ST DeKosky
  • Neurology
  • 2001

Similar Papers

Loading similar papers…